Partial Reconstitution of Photoreceptor cGMP Phosphodiesterase Characteristics in cGMP Phosphodiesterase-5*

Alexey E. GranovskyDagger and Nikolai O. Artemyev§

From the Department of Physiology and Biophysics, University of Iowa College of Medicine, Iowa City, Iowa 52242

Received for publication, January 23, 2001, and in revised form, March 15, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Photoreceptor cGMP phosphodiesterases (PDE6) are uniquely qualified to serve as effector enzymes in the vertebrate visual transduction cascade. In the dark-adapted photoreceptors, the activity of PDE6 is blocked via tight association with the inhibitory gamma -subunits (Pgamma ). The Pgamma block is removed in the light-activated PDE6 by the visual G protein, transducin. Transducin-activated PDE6 exhibits an exceptionally high catalytic rate of cGMP hydrolysis ensuring high signal amplification. To identify the structural determinants for the inhibitory interaction with Pgamma and the remarkable cGMP hydrolytic ability, we sought to reproduce the PDE6 characteristics by mutagenesis of PDE5, a related cyclic GMP-specific, cGMP-binding PDE. PDE5 is insensitive to Pgamma and has a more than 100-fold lower kcat for cGMP hydrolysis. Our mutational analysis of chimeric PDE5/PDE6alpha ' enzymes revealed that the inhibitory interaction of cone PDE6 catalytic subunits (PDE6alpha ') with Pgamma is mediated primarily by three hydrophobic residues at the entry to the catalytic pocket, Met758, Phe777, and Phe781. The maximal catalytic rate of PDE5 was enhanced by at least 10-fold with substitutions of PDE6alpha '-specific glycine residues for the corresponding PDE5 alanine residues, Ala608 and Ala612. The Gly residues are adjacent to the highly conserved metal binding motif His-Asn-X-X-His, which is essential for cGMP hydrolysis. Our results suggest that the unique Gly residues allow the PDE6 metal binding site to adopt a more favorable conformation for cGMP hydrolysis.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

cGMP phosphodiesterases (PDE6)1 play the role of effector enzymes in the vertebrate visual transduction cascade. In retinal rod cells, photoexcited rhodopsin induces GDP/GTP exchange on the visual G protein, transducin (Gt), and liberated Gtalpha GTP activates PDE6. A homologous cascade operates in cone photoreceptors. cGMP hydrolysis by active PDE6 results in the closure of cGMP-gated channels in the plasma membrane (1, 2). The key attributes of the visual cascade, low noise and high gain signal amplification, place specific requirements on PDE6. The enzyme must have a very low basal cGMP hydrolytic rate in the dark-adapted photoreceptors and a very high catalytic rate in the transducin-activated state. This is achieved through two unique features of PDE6: the inhibitory interaction of the catalytic subunits with the gamma -subunit and an exceptionally high kcat value for cGMP hydrolysis when the inhibition is turned off.

The lack of a practical expression system for PDE6 (3-5) has stalled the progress in determining the structural basis of PDE6 function. We have begun to study the structure and function relationship of PDE6 by constructing chimeras between cone PDE6alpha ' and cGMP binding cGMP-specific PDE (PDE5 family) (5, 6). PDE5 and PDE6 display a high degree of identity (45-48%) between the catalytic domains, a strong substrate selectivity for cGMP, and similar sensitivity to a common set of competitive inhibitors (7-9). Yet, the reported maximal rate of cGMP hydrolysis by PDE5 catalytic dimers is only ~10 moles of cGMP per mole of PDE·sec, which is ~400-550-fold lower than the kcat estimates for PDE6 (5, 10-15). Furthermore, the activity of PDE5 is unaffected by the PDE6 gamma -subunit (5, 6). This, and a robust functional expression of PDE5 using the baculovirus/insect cell system (16), makes PDE5 a valuable tool for "gain of PDE6 function" experiments. Recently, we have shown that a substitution of the segment PDE5-(773-820) by the corresponding PDE6alpha '-(737-784) sequence in the wild-type PDE5 or in a PDE5/PDE6alpha ' chimera containing the catalytic domain of PDE5 results in chimeric enzymes capable of inhibitory interaction with Pgamma (6). Alanine-scanning mutational analysis of the previously identified Pgamma cross-linking site, PDE6alpha '-(750-760) (17), revealed a critical Pgamma -interacting residue, Met758 (6). In a model of the PDE6alpha ' catalytic domain, Met758 faces the opening of the catalytic cavity (6). We then hypothesized that Pgamma may interact with additional nonconserved residues located at the perimeter of the cavity, thus allowing Pgamma to serve as a lid on the catalytic pocket. In this study, we mutated three candidate Pgamma contact residues identified from the model of PDE6alpha ' and examined these mutants for inhibition by Pgamma .

The rationale for our search of the catalytic determinants of PDE6 was based on biochemical evidence and the crystal structure of the PDE4 catalytic domain (18-20), which suggests the critical role of the two highly conserved metal binding motifs, His-Asn-X-X-His (I) and His-Asp-X-X-His (II), in the hydrolysis of cyclic nucleotides. We replaced PDE6alpha ' domains containing motifs I and II into PDE5. Resulting chimeric PDEs and corresponding mutants have been analyzed to test our hypothesis.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- cGMP was obtained from Roche Molecular Biochemicals. [3H]cGMP was a product of Amersham Pharmacia Biotech. All restriction enzymes were purchased from New England Biolabs. AmpliTaq® DNA polymerase was a product of PerkinElmer Life Sciences, and Pfu DNA polymerase was a product of Stratagene. Rabbit polyclonal His-probe (H-15) antibodies were purchased from Santa Cruz Biotechnology. Zaprinast and all other reagents were purchased from Sigma.

Cloning of Pgamma Mutants-- Pgamma mutants were generated based on the pET11a-Pgamma expression vector (21, 22). Residues Ile86 and Ile87 were substituted for alanine using PCR-directed mutagenesis. PCR products were obtained using a forward primer containing a NdeI site and a reverse primer containing the mutations and a BamHI site. The fragments were digested with NdeI/BamHI and subcloned into the pET11a-Pgamma digested with the same enzymes.

Preparation of Pgamma and Pgamma Mutants-- The Pgamma -subunit and its mutants were expressed in Escherichia coli and purified on a SP-Sepharose fast flow column and on a C4 HPLC column (Microsorb-MW, Rainin) as described (22). Purified proteins were lyophilized, dissolved in 20 mM HEPES buffer, pH 7.5 and stored at -80 °C until use.

Cloning of Chi20 and Chi21-- The constructs for expression of PDE5/PDE6alpha ' chimeras were obtained based on pFastBacHTb-PDE5 vector (5). To obtain Chi20 and Chi21, original restriction sites in pFastBacHTb-PDE5, SpeI and SphI, were eliminated and re-introduced at desired positions to allow a site-directed cloning of PDE6alpha ' fragments into PDE5. To eliminate two SpeI restriction sites located within the 3'-untranslated region of PDE5 cDNA and the unique SphI site from the multiple cloning sequence of the vector, pFastBacHTb-PDE5 was digested with SpeI/SphI and treated with mung bean nuclease. New SpeI and SphI restriction sites (PDE5 codons for Arg606-His607-Ala608 and Ala618-Leu619-Lys620, respectively) were introduced into the vector using a QuikChangeTM kit (Stratagene). To obtain Chi21 (Fig. 1), a synthetic olygonucleotide duplex, encoding for PDE6alpha '-(561-574), was ligated into the modified pFastBacHTb-PDE5 vector digested with SpeI and SphI. To generate Chi20, a PCR fragment, encoding for PDE6alpha '-(575-617), was digested with SpeI/BlpI and subcloned into the modified pFastBacHTb-PDE5 vector digested with SpeI/BlpI(partial). The resulting construct was digested with SpeI/SphI and ligated to the synthetic oligonucleotide duplex encoding for PDE6alpha '-(561-574).

Site-directed Mutagenesis of PDE5 and Chi16-- Site-directed mutagenesis of PDE5 was performed using a QuikChangeTM kit. A pair of complementary oligonucleotides encoding for the Ala608right-arrowGly and Ala612right-arrowGly substitutions (PDE5A608G/A612G) was used to PCR-amplify the pFastBacHTb-PDE5 vector. The PCR product was treated with DpnI to eliminate the template and was transformed into E. coli DH5alpha . Chi16 mutants with single substitutions of residues Lys769, Phe777, and Phe781 by Ala were constructed using PCR-directed mutagenesis. A unique NheI site (PDE5 codons for Pro661-Leu662) was introduced into Chi16 using a QuikChangeTM kit. The 5'-primer sequence included the NheI recognition site. Reverse primers contained a desired mutation and the StuI site. The PCR products were digested with NheI/StuI and subcloned into the modified Chi16 vector cut with the same enzymes. Sequences of all mutants were verified by automated DNA sequencing at the University of Iowa DNA Core Facility.

Expression and Purification of Recombinant PDEs and their Mutants-- Sf9 cells were harvested at 60 h after infection, washed with 20 mM Tris-HCl buffer, pH 7.8 containing 50 mM NaCl, and resuspended in the same buffer containing a protease inhibitor mixture (10 µg/ml pepstatin, 5 µg/ml leupeptin, and 0.2 mM phenylmethylsulfonyl fluoride). The cell suspensions were sonicated using 30-s pulses for a total duration of 3 min. The supernatants (100,000 × g, 45 min) were loaded onto a column with a His-Bind resin (Novagen) equilibrated with 20 mM Tris-HCl buffer, pH 7.8, containing 10 mM imidazole. The resin was washed with a 5× volume of the buffer containing 500 mM NaCl and 25 mM imidazole. Proteins were eluted with the buffer containing 250 mM imidazole. beta -mercaptoethanol (2 mM) was added to the eluate. PDE5, Chi20, Chi21, and PDE5A608G/A612G were additionally purified using ion-exchange chromatography on a Mono Q® HR 5/5 column (Amersham Pharmacia Biotech). Purified proteins were dialyzed against 40% glycerol and stored at -20 °C.

Other Methods-- PDE activity was measured using [3H]cGMP as described (23, 24). Less than 15% of cGMP was hydrolyzed during these reactions. The Ki values for inhibition of PDE activity by Pgamma and zaprinast were measured using 0.5 µM cGMP (i.e. <35% of the Km value for chimeric and mutant PDEs). Protein concentrations were determined by the method of Bradford (25) using IgG as a standard or by using calculated extinction coefficients at 280 nm. The molar concentrations of Chi20, Chi21, and mutatnt PDEs, [PDE], were calculated based on the fraction of PDE protein in preparations, and the molecular mass of 93.0 kDa. The fractional concentrations of PDE were determined from analysis of the Coomassie Blue-stained SDS gels using a HP ScanJet II CX/T scanner and Scion Image Beta 4.02 software. A typical fraction of Chi16 mutants in partially purified preparations was 10-15%. A typical fraction of purified Chi20, Chi21, and PDE5A608G/A612G was 65-70%. The kcat values for cGMP hydrolysis were calculated as Vmax/[PDE]. SDS-polyacrylamide gel electrophoresis was performed by the method of Laemmli (26) in 10-12% acrylamide gels. For Western immunoblotting, proteins were transferred to nitrocellulose (0.1 µm, Schleicher & Schuell) and analyzed using rabbit His-probe (H-15) or sheep anti-PDE6alpha ' antibodies (5, 6, 27). The antibody-antigen complexes were detected using anti-rabbit or anti-goat/sheep IgG conjugated to horseradish peroxidase and ECL reagent (Amersham Pharmacia Biotech.). Fitting the experimental data to equations was performed with nonlinear least squares criteria using GraphPad Prizm Software. The Ki, Km, and IC50 values are expressed as mean ± S.E. for three independent measurements.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Mutational Analysis of the Pgamma Binding Site of PDE6alpha '-- Previously, we demonstrated that PDE5/PDE6alpha ' chimeras containing a PDE6alpha ' sequence, PDE6alpha '-(737-784), are effectively inhibited by Pgamma , and two residues, Met758 and Gln752, participate in the inhibitory interaction (6). Based on the model structure of PDE6alpha ' (6), three solvent-exposed nonconserved PDE6alpha ' residues, Lys769, Phe777, and Phe781, were chosen for further mutational analysis of the Pgamma binding region (Fig. 1A). A PDE5/PDE6alpha ' chimera, Chi16 (6), served as a template for single substitutions of these residues by Ala. The Chi16 mutants were expressed in Sf9 insect cells and partially purified. Expression of the K769A, F777A, and F781A mutants have yielded similar amounts of soluble protein (50-100 µg/100 ml of culture). Neither of these mutations has significantly affected the catalytic properties of chimeric PDE. The Km and kcat values for cGMP hydrolysis for all three mutants were in the 3-10 µM range, and the 5-10 s-1 range, respectively (Table I). As an additional control for the structural integrity of the catalytic site, mutants of Chi16 were tested for the PDE activity inhibition by zaprinast, a specific competitive inhibitor of PDE5 and PDE6. The largest change, a 2-fold increase in the IC50 value, was caused by the F781A substitution (Table I). Nonetheless, such a change represents an insignificant loss of affinity to zaprinast.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 1.   Construction and expression of PDE5/PDE6alpha ' chimeras and mutants in Sf9 cells. A, schematic representation of PDE5/PDE6alpha ' chimeras. The PDE6alpha ' residues substituted by Ala in Chi16 and the metal binding motifs I and II are shown. The PDE6 and PDE5 motifs I are identical. B, an SDS-polyacrylamide gel (12%) of purified PDE5, Chi20, Chi21, and PDE5A608G/A612G (2 µg per lane) stained with Coomassie Blue. The recombinant His6-tagged proteins were expressed in Sf9 cells and partially purified using chromatography on a His-Bind resin and HPLC on a Mono Q® HR 5/5 column as described under "Experimental Procedures."

                              
View this table:
[in this window]
[in a new window]
 
Table I
Functional properties of PDE5/PDE6alpha ' chimeras
PDE activity was measured using [3H]cGMP (24). The Km values of PDE6alpha ' or PDE5 and PDE5/PDE6alpha ' chimeras were determined in the presence of 0.1 µCi [3H]cGMP and 0.1-500 µM of unlabeled cGMP. The Ki and IC50 values for inhibition of PDE activity by Pgamma and zaprinast were measured using 0.5 µM cGMP. The results are presented as the mean ± S.E. for three independent measurements.

The test of the ability of Chi16 mutants to be inhibited by Pgamma showed that the K769A mutation had no effect on the inhibitory interaction with Pgamma (Ki 2.9 nM) (Table I). Two other mutants, F777A and F781A, displayed significant impairments in the inhibition by Pgamma . The F777A substitution reduced both the maximal inhibition of PDE activity by Pgamma (~45%) and the Ki value (Ki of 19 nM). The inhibition of F781A mutant by Pgamma also was incomplete (~65%) and associated with an increase in the Ki value (Ki of 31 nM) (Fig. 2A and Table I).


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of Pgamma and C-terminal Pgamma mutants on the catalytic activity of tPDE6alpha ' Chi16 and Chi16 mutants. A, inhibition of Chi16, F777A, and F781A PDE activity by Pgamma . The activities of Chi16 (), F777A (black-triangle), and F781A (black-down-triangle ) (50-100 pM) were determined upon addition of increasing concentrations of Pgamma . Reactions were initiated by addition of 0.5 µM of cGMP. The Ki values (nM) calculated from the inhibition curves were 3.6 ± 0.4 (), 19 ± 2 (black-triangle), and 31 ± 5 (black-down-triangle ). B, inhibition of tPDE6alpha ' () (0.5 pM), Chi16 (), F777A (black-triangle), and F781A (black-down-triangle ) by Pgamma I86A. The Ki values (nM) calculated from the inhibition curves were 0.75 ± 0.08 (), 13 ± 1 (), 96 ± 13 (black-triangle), and 49 ± 8 (black-down-triangle ). C, inhibition of tPDE6alpha ' (), Chi16 (), F777A (black-triangle), and F781A (black-down-triangle ) by Pgamma I87A. The Ki values (nM) calculated from the inhibition curves were 0.65 ± 0.04 (), 6.6 ± 1.0 (), 64 ± 8 (black-triangle), and 32 ± 2 nM (black-down-triangle ).

Effects of the C-terminal Pgamma Mutants on the Catalytic Activity of Mutant Chi16-- C-terminal Pgamma mutants were designed based on the evidence for the critical role of the Pgamma C terminus in PDE6 inhibition (21, 28). The two extreme C-terminal Pgamma residues, Ile86 and Ile87, were replaced by Ala to obtain the Pgamma I86A and Pgamma I87A mutants, respectively. The Pgamma mutants were analyzed for their ability to inhibit trypsin-activated PDE6alpha ' (tPDE), Chi16, and the M758A, F777A, and F781A mutants (Fig. 2; Table I). Pgamma I86A and Pgamma I87A fully inhibited tPDE activity. However, the potency of the inhibition was reduced ~4-5-fold (Ki of 0.75 nM for Pgamma I86A and Ki of 0.65 nM for Pgamma I87A, compared with Ki of 0.15-0.2 nM for Pgamma ). A similar increase in the Ki values was observed from the inhibition of Chi16 activity by Pgamma I86A (Ki of 13 nM) and Pgamma I87A (Ki of 7 nM) (Fig. 2, B and C; Table I). Yet, Pgamma I86A and Pgamma I87A did not fully inhibit Chi16, maximal inhibition was 65 and 70%, respectively. (Fig. 2, B and C; Table I). No appreciable inhibition of M758A by either Pgamma mutant was seen even at inhibitor concentrations as high as 5 µM. The inhibition of F777A by Pgamma I86A was partial (45%) with the Ki value of 96 nM, whereas Pgamma I87A inhibited this Chi16 mutant with an even smaller maximal effect (25%, Ki of 64 nM). The F781A mutant was inhibited by Pgamma I86A and Pgamma I87A with Ki values of 49 and 32 nM and maximal effects of 40 and 55%, respectively (Fig. 2, B and C; Table I).

Catalytic Properties of PDE5/PDE6alpha ' Chimeras Containing the PDE6alpha ' Metal Binding Sites-- Two conserved metal binding motifs found in all PDEs are absolutely critical for cyclic nucleotide hydrolytic activity (18-20). To identify the structural elements responsible for the unique catalytic properties of PDE6, chimeric PDE5/PDE6alpha ' have been generated by introduction into PDE5 of PDE6alpha ' domains containing metal binding motifs, I and II. A replacement of the PDE6alpha '-(562-617) segment into PDE5 yields a chimeric PDE5/PDE6alpha ', Chi20, that incorporates both PDE6alpha ' metal binding sites and the connecting sequence (Fig. 1A). Chi20 was expressed in Sf9 cells as a functional enzyme at ~400 µg/100 ml and purified to ~ 65-70% purity (Fig. 1B). The catalytic characteristics of Chi20 were examined in comparison to those of PDE5 and native PDE6alpha '. PDE6alpha ' has reported Km (17-25 µM) and kcat (3500-4500 moles of cGMP per mole of PDE·s) values for cGMP hydrolysis that are ~5 and ~400-fold higher than the respective constants for PDE5 (5, 10-11, 14). The catalytic parameters of Chi20 were significantly different from those of PDE5. Chi20 hydrolyzed cGMP with the Km value of 12 µM, which is ~4-fold higher than the Km value for PDE5 but similar to that of PDE6alpha ' (Table I). The maximal activity of 116 moles of cGMP per mole of PDE·s for Chi20 is ~10-fold higher than that of PDE5. Chi20 was inhibited by zaprinast with the IC50 value of 0.35 µM, which is comparable with that of PDE5 (Table I).

To determine the role of individual metal binding motifs and their adjacent regions in cGMP hydrolysis by PDE6, we inserted a PDE6alpha ' fragment corresponding to the helix-alpha 6 (20), PDE6alpha '-(562-574), into PDE5 (Chi21) (Fig. 1). The catalytic properties of Chi21 and the inhibition by zaprinast (Km of 17 µM, kcat of 110 moles of cGMP per mole of PDE·s, and IC50 0.39 µM) were similar to those of Chi20.

Catalytic Properties of the PDE5A608G/A612G Mutant-- The alignment of sequences from different PDE families corresponding to the alpha 6 helix shows a glycine residue, PDE6alpha 'Gly562, conserved only in photoreceptor PDEs (Fig. 3A). A second Gly residue, PDE6alpha 'Gly566, is conserved in PDE6alpha ' and PDE6alpha , but substituted by Ala in PDE6beta and PDE5 (Fig. 3A). To test the hypothesis that Gly562 and Gly566 of PDE6alpha ' are responsible for the differences in catalytic properties of Chi21 and PDE5, a doubly substituted mutant of PDE5, A608G and A612G, was expressed and purified from Sf9 cells. Similar to Chi20 and Chi21, PDE5A608G/A612G hydrolyzed cGMP with a Km value of 14 µM and a kcat value of 105 moles of cGMP per mole of PDE·s (Table I).


View larger version (63K):
[in this window]
[in a new window]
 
Fig. 3.   The Pgamma C terminus docked to the PDE6alpha ' catalytic site. A, an alignment (31) of PDE1-6 sequences corresponding to the helix-alpha 6 (20). B and C, a model of the PDE6alpha ' was generated with SWISS-MODEL (32) using the coordinates of the PDE4 structure as a template (20). The Pgamma C terminus binding residues, Gln752, Met758, Phe777, and Phe781 are shown in red. The metal ions Zn2+ and Mg2+ are shown in yellow and magenta, respectively. The C terminus of Pgamma , Pgamma -(75-87), was generated and manually docked to the catalytic site using SYBYL (v.6.7) (Tripos Associates, St. Louis, MO). C, the clipped view is a 900 counterclockwise rotation around the vertical axis shown in B.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

An interaction between PDE6 catalytic and inhibitory Pgamma -subunits keeps the visual effector enzyme inhibited in the dark. Previous biochemical studies have established that the gamma -subunit of photoreceptor PDE inhibits the enzyme activity by blocking its catalytic site (29). The major inhibitory domain has been localized to the Pgamma C terminus (21, 28). Recently, we have demonstrated that Pgamma inhibits the activity of PDE5/PDE6alpha ' chimera, Chi 16, containing residues PDE6alpha '-(737-784) (6). Essential Pgamma binding residues, Gln752 and Met758, of PDEalpha ' have been identified via mutagenesis of Chi16 (6). A model of the PDE6alpha ' catalytic domain places Met758 at the opening of the catalytic pocket (6). Hypothetically, to ensure an effective catalytic block, the Pgamma C terminus may lie over or might be inserted into the catalytic cavity. The former appears more likely because the catalytic pockets of different cyclic nucleotide PDEs are made up of highly conserved residues, whereas the inhibition by Pgamma is a unique attribute of PDE6. We speculated that to cover the catalytic pocket, the Pgamma C terminus, besides Met758, interacts with additional nonconserved residues located at the perimeter of the entrance to the active site. The fact that the introduction of PDE6alpha '-(737-784) into PDE5/PDE6alpha ' chimera leads to a full inhibition of the PDE activity by Pgamma suggests the PDE6alpha '-(737-784) segment contains most if not all residues interacting with the Pgamma C terminus. In the PDE6alpha ' model, PDE6alpha '-(737-784) comprises about half of the catalytic cavity mouth. Residues at three positions within PDE6alpha '-(737-784) (Lys769, Phe777, and Phe781) are conserved among photoreceptor PDEs but have nonhomologous substitutions in PDE5. Supporting our hypothesis, replacement of two residues, Phe777 and Phe781, by Ala in Chi16 has resulted in mutant PDEs that in comparison with Chi16 were less potently and incompletely inhibited by Pgamma . Phe777 and Phe781 are located next to each other, opposite to the Met758 side of the catalytic opening (Fig. 3, B and C). Thus, it appears that the Pgamma C terminus makes a bridge over the catalytic pocket. Such a model provides an interesting explanation to the results of an earlier study that examined inhibition of PDE6 by C-terminally truncated Pgamma mutants (21). Truncations of one or two of the C-terminal Ile86-Ile87 residues led to substantial increases in the Ki value, whereas further truncations, up to 8-11 C-terminal residues, reduced the maximal inhibition of PDE6 activity without significantly affecting the Ki value (21). A plausible interpretation is that Pgamma Ile86-Ile87 interact with residues on one side of the catalytic pocket and other residues, perhaps Pgamma -(77-85), stretch over the catalytic cavity until Pgamma reaches the opposite side. Accordingly, removal of Pgamma Ile86-Ile87 decreases the affinity of Pgamma for the PDE6 catalytic subunit, whereas progressive removal of Pgamma -(77-85) residues gradually facilitates access of cGMP to the catalytic site. To determine the orientation of the Pgamma C terminus against the catalytic site and identify point-to-point interactions with PDE6alpha ', we examined the inhibition of Chi16 and the M758A, F777A, and F781A mutants of Chi16 by two Pgamma mutants, Pgamma I86A and Pgamma I87A. The simplest prediction is that if a C-terminal Ile of Pgamma interacts with one of the three PDE6alpha ' residues, the corresponding mutant PDE would be inhibited comparably by Pgamma and by the Pgamma mutant. Complicating this prediction, side chains of Phe777 and Phe781 make a hydrophobic contact and thereby may support each other in the interaction with Pgamma . The analysis of inhibition of Chi16 mutants by Pgamma mutants indicates that Ile86 and Ile87 of Pgamma interact with Phe777 and Phe781 of PDE6alpha '. Moderate increases in the Ki values and reductions in the maximal inhibition of F777A and F781A caused by the Pgamma I86A substitution suggest that Ile86 probably contacts one or both the PDE6alpha ' residues. The failure of Pgamma I86A to inhibit M758A is consistent with the notion that Ile86 binds Phe777/781, but not Met758. The lack of inhibition is likely caused by the inability of M758A and Pgamma I86A to establish at least two of the three critical contacts involving Met758, Phe777, and Phe781. The Pgamma I87A mutant did not appreciably inhibit the activity of the M758A mutant PDE. Pgamma I87A inhibited F781A stronger than F777A pointing to a probable contact between Pgamma Ile87 and Phe781 of PDE6alpha '. The incomplete inhibition of mutant PDEs by Pgamma or Pgamma mutants most likely reflects equivalent partial inhibition of both active sites of the catalytic dimer, rather than the loss of inhibition at one site.

The analysis of Pgamma secondary structure predicts an alpha -helical structure for the C-terminal residues Pgamma -(75-84) (30). The C terminus of Pgamma , Pgamma -(75-87), manually docked to the PDE6alpha ' catalytic site is shown in Fig. 3, B and C. The model assumes the helical structure of Pgamma -(75-84) and the contacts between Pgamma Ile86-Ile87 and PDE6alpha 'Phe777-Phe781. This orientation of Pgamma is also consistent with Gln752 of PDE6alpha ' (6) making a contact with a Pgamma residue located N-terminally to Pgamma -(75-87).

The remarkable ability of photoreceptor PDEs to hydrolyze cGMP with a catalytic rate constant of ~4000-5500 moles of cGMP per mole of PDE·s (12-15) is essential to the signal amplification in the visual cascade. All catalytic subunits of cyclic nucleotide PDEs contain two strictly conserved metal binding motifs, His-Asn-X-X-His (motif I) and His-Asp-X-X-His (motif II). In PDE6alpha ' these motifs are as follows: 557His-Asn-Trp-Arg-His561 and 597His-Asp-Ile-Asp-His601. The crucial role of the metal ions and the binding motifs for PDE catalytic activity has been recently supported by a crystallographic study of the PDE4 catalytic domain (20). Rather than forming separate metal binding sites, both motifs are involved in coordination of two bound metal ions, ME1 and ME2 (20). For example, ME1, most likely a tightly bound Zn2+, is coordinated by the His residue (His561 of PDE6alpha ') from motif I, and the His and Asp residues from motif II (His597-Asp598). A model of cAMP docked in the PDE4 active site demonstrates that ME1 and ME2 bind the cyclic phosphate, position a potential water molecule for the nucleophilic attack, and would serve to stabilize the transition state (20). In view of the role of metal binding sites in hydrolysis of cyclic nucleotides, we have considered the motifs I and II as probable structural determinants of the catalytic properties of PDE6. Motifs I and II are practically identical in PDE5 and PDE6. Therefore, a spatial orientation of these sites might be a potential key factor for cGMP hydrolysis. Motif I comprises the N-terminal potion of the helix-alpha 6, and motif II is in the loop connecting helices 7 and 8. A PDE5/PDE6alpha ' chimera, Chi20, was generated by replacing a PDE6alpha ' domain containing helices alpha 6-alpha 8 into PDE5. The analysis of Chi20 revealed a more than 10-fold increase in the maximal catalytic rate accompanied by a ~5-fold increase in the Km value. Subsequent chimeric PDE, Chi21, containing only helix alpha 6 of PDE6alpha ' displayed catalytic properties similar to those of Chi20. An alignment of sequences of photoreceptor PDEs and PDE5 corresponding to the helix-alpha 6 shows a high degree of homology with the notable exception of residues at two positions corresponding to PDE6alpha ' Gly562 and Gly566. Gly562 of PDE6alpha ' is conserved only in the PDE6 family, but substituted by Ala in PDE5 (Fig. 3A). Importantly, Gly562 immediately follows His561 from motif I. His561, by analogy to PDE4, is involved in coordination of ME1, and in the positioning of His557 to accomplish the protonation of the O3' leaving group (20). To probe the role of the Gly residues, a doubly substituted PDE5 mutant, A608G/A612G, has been made. The kcat value of the A608G/A612G mutant was comparable with those of Chi20 and Chi21, and ~10-fold higher then that of PDE5. These results suggest that the Gly residues are in part responsible for the catalytic characteristics of PDE6. Most likely, they allow for a positioning of motif I that is most favorable for cGMP hydrolysis. Other yet to be defined determinants contribute to the unique catalytic power of PDE6, because the achieved kcat value is still ~40-50-fold lower than kcat described for native activated PDE6. Overall, our results suggest that a progressive incorporation of PDE6 domains or residues into PDE5 not only allows a structure-function analysis of PDE6, but also represents a realistic approach to generate a chimeric enzyme that would be functionally indistinguishable from PDE6.

    ACKNOWLEDGEMENT

We thank Boyd Knosp for assistance with molecular modeling.

    FOOTNOTES

* This work was supported by National Institutes of Health (NIH) Grant EY-10843. The services provided by the Diabetes and Endocrinology Research Center of the University of Iowa were supported by NIH Grant DK-25295.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Recipient of the American Heart Association Heartland Affiliate Predoctoral Fellowship.

§ Established Investigator of the American Heart Association. To whom correspondence should be addressed. Tel.: 319-335-7864; Fax: 319-335-7330; E-mail: nikolai-artemyev@uiowa.edu.

Published, JBC Papers in Press, April 2, 2001, DOI 10.1074/jbc.M100626200

    ABBREVIATIONS

The abbreviations used are: PDE, cGMP phosphodiesterase; Pgamma , gamma -subunit of PDE6; PDE6alpha ', alpha '-subunit of cone PDE6; PDE5, cGMP binding, cGMP-specific PDE (PDE5 family); PCR, polymerase chain reaction; HPLC, high performance liquid chromatography.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Chabre, M., and Deterre, P. (1989) Eur. J. Biochem. 179, 255-266[Medline] [Order article via Infotrieve]
2. Yarfitz, S., and Hurley, J. B. (1994) J. Biol. Chem. 269, 14329-14332[Free Full Text]
3. Piriev, N. I., Yamashita, C., Samuel, G., and Farber, D. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 9340-9344[Abstract]
4. Qin, N., and Baehr, W. (1994) J. Biol. Chem. 269, 3265-3271[Abstract/Free Full Text]
5. Granovsky, A. E., Natochin, M., McEntaffer, R. L., Haik, T. L., Francis, S. H., Corbin, J. D, and Artemyev, N. O. (1998) J. Biol. Chem. 273, 24485-24490[Abstract/Free Full Text]
6. Granovsky, A. E., and Artemyev, N. O. (2000) J. Biol. Chem. 275, 41258-41262[Abstract/Free Full Text]
7. McAllister-Lucas, L. M., Sonnenburg, W. K., Kadlecek, A., Seger, D., Trong, H. L., Colbran, J. L., Thomas, M. K., Walsh, K. A., Francis, S. H., Corbin, J. D., and Beavo, J. A. (1993) J. Biol. Chem. 268, 22863-22873[Abstract/Free Full Text]
8. Gillespie, P. G., and Beavo, J. A. (1989) Mol. Pharmacol. 36, 773-781[Abstract]
9. Turko, I. V., Ballard, S. A., Francis, S. H., and Corbin, J. D. (1999) Mol. Pharmacol. 56, 124-130[Abstract/Free Full Text]
10. Thomas, M. K., Francis, S. H., and Corbin, J. D. (1990) J. Biol. Chem. 265, 14964-14970[Abstract/Free Full Text]
11. Turko, I. V., Francis, S. H., and Corbin, J. D. (1998) J. Biol. Chem. 273, 6460-6466[Abstract/Free Full Text]
12. Mou, H., Grazio, H. J., III, Cook, T. A., Beavo, J. A., and Cote, R. H. (1999) J. Biol. Chem. 274, 18813-18820[Abstract/Free Full Text]
13. Leskov, I. B., Klenchin, V. A., Handy, J. W., Whitlock, G. G., Govardovskii, V. I., Bownds, M. D., Lamb, T. D., Pugh, E. N., and Arshavsky, V. Y. (2000) Neuron 27, 525-537[Medline] [Order article via Infotrieve]
14. Gillespie, P. G., and Beavo, J. A. (1988) J. Biol. Chem. 263, 8133-8141[Abstract/Free Full Text]
15. Dumke, C. L., Arshavsky, V. Y., Calvert, P. D., Bownds, M. D., and Pugh, E. N., Jr. (1994) J. Gen. Physiol. 103, 1071-1098[Abstract]
16. Turko, I. V., Haik, T. L., McAllister-Lucas, L. M., Burns, F., Francis, S. H., and Corbin, J. D. (1996) J. Biol. Chem. 271, 22240-22244[Abstract/Free Full Text]
17. Artemyev, N. O., Natochin, M., Busman, M., Schey, K. L., and Hamm, H. E. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 5407-5412[Abstract/Free Full Text]
18. Francis, S. H., Turko, I. V., Grimes, K. A., and Corbin, J. D. (2000) Biochemistry 39, 9591-9596[CrossRef][Medline] [Order article via Infotrieve]
19. He, F., Seryshev, A. B., Cowan, C. W., and Wensel, T. G. (2000) J. Biol. Chem. 275, 20572-20577[Abstract/Free Full Text]
20. Xu, R. X., Hassell, A. M., Vanderwall, D., Lambert, M. H., Holmes, W. D., Luther, M. A., Rocque, W. J., Milburn, M. V., Zhao, Y., Ke, H., and Nolte, R. T. (2000) Science 288, 1822-1825[Abstract/Free Full Text]
21. Skiba, N. P., Artemyev, N. O., and Hamm, H. E. (1995) J. Biol. Chem. 270, 13210-13215[Abstract/Free Full Text]
22. Artemyev, N. O., Arshavsky, V. Y., and Cote, R. H. (1998) Methods 14, 93-104[CrossRef][Medline] [Order article via Infotrieve]
23. Thompson, W. J., and Appleman, M. M. (1971) Biochemistry 10, 311-316[Medline] [Order article via Infotrieve]
24. Natochin, M., and Artemyev, N. O. (2000) Methods Enzymol. 315, 539-554[Medline] [Order article via Infotrieve]
25. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254[CrossRef][Medline] [Order article via Infotrieve]
26. Laemmli, U. K. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]
27. Towbin, H., Staehelin, T., and Gordon, J. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 4350-4354[Abstract]
28. Brown, R. L. (1992) Biochemistry 31, 5918-5925[Medline] [Order article via Infotrieve]
29. Granovsky, A. E., Natochin, M., and Artemyev, N. O. (1997) J. Biol. Chem. 272, 11686-11689[Abstract/Free Full Text]
30. Rost, B. (1996) Methods Enzymol. 266, 525-539[CrossRef][Medline] [Order article via Infotrieve]
31. Thompson, J. D., Higgins, D. G., and Gibson, T. J. (1994) Nucleic Acids Res. 22, 4673-4680[Abstract]
32. Guex, N., and Peitsch, M. C. (1997) Electrophoresis 18, 2714-2723[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.



This Article
Abstract
Full Text (PDF)
All Versions of this Article:
276/24/21698    most recent
M100626200v1
Purchase Article
View Shopping Cart
Alert me when this article is cited
Alert me if a correction is posted
Citation Map
Services
Email this article to a friend
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Copyright Permissions
Google Scholar
Articles by Granovsky, A. E.
Articles by Artemyev, N. O.
Articles citing this Article
PubMed
PubMed Citation
Articles by Granovsky, A. E.
Articles by Artemyev, N. O.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   Biochemistry and Molecular Biology Education 
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.